Most of the exposure to misinformation about cancer treatment occurs in conversations with family and friends and on social ...

Rhapsido is the first and only Bruton’s tyrosine kinase (BTK) inhibitor approved for chronic spontaneous urticaria (CSU).

SCAN Health Plan will expand its 2026 Medicare Advantage benefits with $0 copays and higher dental, vision and allowance coverage amid funding and coverage cuts from larger insurers such as ...

Pfizer only offered to discount six products through the Most Favored Nation program, and healthcare policy experts suggest the real-world impact remains uncertain.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

In a recent trial, verapamil showed a trend toward preserving insulin-producing beta cells in patients with Type 1 diabetes but failed to achieve statistical significance.

Enrollment in Medicare Advantage Special Needs Plans (SNPs) has grown steadily since becoming permanent in 2018, now ...

Panelists discuss how maintaining patients on effective single therapies for Crohn’s disease is preferable to switching ...

Novartis said that it is exploring an additional direct-to-employer model to increase access and affordability for ...

In this conversation with Kristin Begley, chief commercial officer at Capital Rx, we discussed the company’s recent rebrand ...

Tavapadon is an investigational, novel, once-daily treatment option for Parkinson’s disease, which currently affects more ...

If approved, Awiqli would become the first once-weekly basal insulin available in the United States for adults with Type 2 ...